ciltacabtagene autoleucel
legend biotech,janssen
['multiple myeloma', 'cartitude-1', 'cilta-cel', 'legn']
 $legn - data from cartitude program - median follow-up data from the cartitude-1 study of cilta-cel in patients with relapsed or refractory multiple myeloma presented at the 2022 asco annual meeting
overall response rate remains at 98 percent after more than two years
The greatest danger to the State is independent intellectual criticism. — Murray Rothbard